Teva Pharmaceutical Industries Limited
TEVA
$36.77
$0.250.69%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 4.02% | -15.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.02% | -15.47% | |||
| Cost of Revenue | -1.09% | -2.19% | |||
| Gross Profit | 9.23% | -25.76% | |||
| SG&A Expenses | 3.40% | -10.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -28.57% | 17.65% | |||
| Total Operating Expenses | 23.49% | -6.04% | |||
| Operating Income | -78.11% | -40.62% | |||
| Income Before Tax | -204.36% | 384.44% | |||
| Income Tax Expenses | 80.60% | 117.18% | |||
| Earnings from Continuing Operations | -256.10% | -23.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -256.10% | -23.13% | |||
| EBIT | -78.11% | -40.62% | |||
| EBITDA | -59.28% | -35.15% | |||
| EPS Basic | -254.89% | -23.60% | |||
| Normalized Basic EPS | -110.35% | -49.43% | |||
| EPS Diluted | -259.48% | -24.13% | |||
| Normalized Diluted EPS | -110.55% | -49.37% | |||
| Average Basic Shares Outstanding | 0.78% | 0.61% | |||
| Average Diluted Shares Outstanding | -1.19% | 0.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||